SAVA icon

Cassava Sciences

2.80 USD
-0.04
1.41%
At close Mar 24, 4:00 PM EDT
After hours
2.80
+0.00
0.00%
1 day
-1.41%
5 days
1.82%
1 month
12.00%
3 months
19.66%
6 months
-90.53%
Year to date
1.82%
1 year
-85.79%
5 years
-9.97%
10 years
-70.21%
 

About: Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Employees: 30

0
Funds holding %
of 7,390 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

26% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 35

6.87% more ownership

Funds ownership: 29.27% [Q3] → 36.13% (+6.87%) [Q4]

14% less funds holding

Funds holding: 160 [Q3] → 137 (-23) [Q4]

38% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 52

63% less call options, than puts

Call options by funds: $10.1M | Put options by funds: $27.2M

87% less capital invested

Capital invested by funds: $412M [Q3] → $51.8M (-$360M) [Q4]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for SAVA.

Financial journalist opinion

Positive
Zacks Investment Research
2 weeks ago
Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?
Cassava Sciences (SAVA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?
Neutral
GlobeNewsWire
3 weeks ago
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
AUSTIN, Texas, March 03, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, including Alzheimer's disease and tuberous sclerosis complex (TSC)-related seizures, today reported financial results for the year ended December 31, 2024 and provided a business update.
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
Neutral
Accesswire
1 month ago
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128597&wire=1 or contact Joseph E. Levi, Esq.
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact Levi & Korsinsky
Neutral
Accesswire
1 month ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128562&wire=1 or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
Neutral
Accesswire
1 month ago
Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights – SAVA
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128534&wire=1 or contact Joseph E. Levi, Esq.
Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights – SAVA
Neutral
Accesswire
1 month ago
SAVA LAWSUIT ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128502&wire=1 or contact Joseph E. Levi, Esq.
SAVA LAWSUIT ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Neutral
PRNewsWire
1 month ago
SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
NEW YORK , Feb. 10, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. So what: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
Neutral
GlobeNewsWire
1 month ago
Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SAVA
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.
Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SAVA
Neutral
Accesswire
1 month ago
Cassava Sciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128462&wire=1 or contact Joseph E. Levi, Esq.
Cassava Sciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
Neutral
Accesswire
1 month ago
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc.(SAVA) Shareholders
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128349&wire=1 or contact Joseph E. Levi, Esq.
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc.(SAVA) Shareholders
Charts implemented using Lightweight Charts™